证券代码：688075 证券简称：安旭生物 公告编号：2025-029 杭州安旭生物科技股份有限公司 关于产业基金完成注销登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、产业基金情况概述 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"） 于 2022 年 6 月 2 日召开的公司第一届董事会第二十四次会议，审议通过了《关于公司参与设 立产业投资基金的议案》，同意公司与中传金控（天津）股权投资基金管理有限 公司及国瀚投资管理（北京）有限公司出资发起设立杭州传旭股权投资合伙企业 （有限合伙）（以下简称 "产业基金"或"基金"），主要投资处于创业期、成 长期的医药、大健康、生物医药等领域企业/项目。详见公司于 2022 年 6 月 3 日在 上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体披露的《安旭生物关 于参与设立产业投资基金的公告》（公告编号：2022-032）。 基金名称：杭州传旭股权投资合伙企业（有限合伙） 基金类型：有限合伙企业 基金规模：10亿元人民币 执行事务合伙 ...

Market Overview - The Shanghai Composite Index closed at 3872.88 points, up 1.17%, with a total trading volume of 1.7438 trillion yuan [1] - As of the current date, 94 A-shares have surpassed their annual moving average [1] Stocks Surpassing Annual Moving Average - Notable stocks with significant deviation rates include: - Kaiwang Technology (301182) with a deviation rate of 15.21% and a daily increase of 17.68% [1] - Wanli Stone (002785) with a deviation rate of 9.52% and a daily increase of 10.01% [1] - Daqing Huake (000985) with a deviation rate of 9.44% and a daily increase of 10.00% [1] - Other stocks with smaller deviation rates include: - China CNR (601990) and Beidahuang (000995), both just above their annual moving average [1] Additional Stocks with Positive Performance - Other stocks showing positive performance include: - Tonghui Information (430090) with a daily increase of 6.20% and a deviation rate of 4.69% [1] - Huangtai Liquor (000995) with a daily increase of 5.17% and a deviation rate of 4.47% [1] - Nanjing Securities (601990) with a daily increase of 4.09% and a deviation rate of 4.00% [1]

融券方面，安旭生物9月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 机构持仓方面，截止2025年6月30日，安旭生物十大流通股东中，广发价值核心混合A（010377）位居 第五大流通股东，持股301.47万股，持股数量较上期不变。招商景气优选股票A（009864）位居第八大 流通股东，持股60.00万股，相比上期减少1.00万股。博时凤凰领航混合A（013450）位居第九大流通股 东，持股52.89万股，为新进股东。 资料显示，杭州安旭生物科技股份有限公司位于浙江省杭州市莫干山路1418-50号4幢5层，成立日期 2008年7月4日，上市日期2021年11月18日，公司主营业务涉及POCT试剂及仪器的研发、生产与销售。 主营业务收入构成为：快速诊断试剂100.00%。 责任编辑：小浪快报 截至6月30日，安旭生物股东户数6024.00，较上期增加1.50%；人均流通股21096股，较上期减少 1.48%。2025年1月-6月，安旭生物实现营业收入2.30亿元，同比减少7.42%；归母净利润59 ...

Core Viewpoint - Anxu Bio has demonstrated resilience in the IVD industry by achieving a 24% increase in net profit excluding non-recurring items and a staggering 1420.52% increase in operating cash flow, despite the overall industry downturn in the first half of 2025 [1][2][3] Financial Performance - Initial impressions from Anxu Bio's half-year report show a revenue decline of 7.42% and a net profit drop of 48.57%, which can be misleading [2] - The decline in net profit is attributed to macroeconomic factors such as currency fluctuations and reduced government subsidies, rather than poor business performance [2] - The company's net profit excluding non-recurring items reached 23.5862 million yuan, reflecting a year-on-year increase of 24.85%, indicating strong core business performance [2] Cash Flow and Operational Efficiency - Anxu Bio reported a net operating cash flow of 3.52 million yuan, which is 15 times that of the same period last year, highlighting its ability to convert profits into cash effectively [3] - The increase in cash flow is due to improved accounts receivable turnover and better inventory management, showcasing the company's operational efficiency [3] R&D Investment and Certifications - Anxu Bio invested 20.64% of its revenue in R&D, significantly higher than the industry average of around 15%, focusing on long-term barriers rather than short-term products [4] - The company has obtained a total of 1,728 product certifications, with 148 new certifications in the first half of 2025, including 133 international certifications, establishing a strong competitive edge [4] Global Market Position - Anxu Bio's revenue is 90% derived from overseas markets, allowing it to avoid the price pressures associated with domestic centralized procurement [6] - The stability of orders from clients in Europe, Southeast Asia, and the established certification barriers contribute to the company's secure revenue base [6] Domestic Market Expansion - The company is accelerating its domestic market strategy, launching significant products such as the "Respiratory Virus Antigen Detection Pen" and "Chest Pain Triad Pen," targeting urgent clinical needs [7] - Anxu Bio is transitioning from an OEM to a self-branded model, with a current gross margin of 39%, which is expected to increase as its brand penetrates the market [7] New Business Opportunities - Anxu Bio is exploring new growth avenues in pet diagnostics and chronic disease management, with the global veterinary IVD market growing at 10.5% annually [8] - The introduction of the GluMate app for chronic disease management aims to create a closed-loop service model, integrating testing, data, and healthcare services [8][9] Strategic Outlook - Anxu Bio's strategy combines defensive measures, such as high overseas revenue and extensive certifications, with offensive initiatives in domestic markets and new business segments [10] - The company's shift from a product-centric to an ecosystem-oriented business model is expected to enhance its valuation and open new growth opportunities [10]

证券代码：688075 证券简称：安旭生物 公告编号：2025-028 杭州安旭生物科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?会议召开时间：2025 年 9 月 22 日 （星期一） 14:00-15:00 ? 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） ?会议召开方式：上证路演中心网络互动 ?投资者可于 2025 年 9 月 15 日 （星期一） 至 9 月 19 日 （星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jun.yu@diareagent.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 杭州安旭生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 20 日 发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年 ...

证券日报网讯9月3日晚间，安旭生物发布公告称，公司计划于2025年9月22日(星期一)14：00-15：00举 行2025年半年度业绩说明会。 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-028 杭州安旭生物科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 22 日 （星期一） 14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 09 月 22 日 （星期一） 14:00-15:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 15 日 （星期 ...

Core Viewpoint - Anxu Bio experienced a decline in stock price and revenue, indicating potential challenges in its financial performance and market position [1][2]. Financing and Trading Activity - On August 27, Anxu Bio's stock fell by 2.70%, with a trading volume of 46.83 million yuan. The financing buy-in amounted to 15.09 million yuan, while financing repayment was 14.76 million yuan, resulting in a net financing buy of 0.33 million yuan [1]. - As of August 27, the total financing and securities lending balance for Anxu Bio was 97.20 million yuan, which represents 1.88% of its market capitalization. This financing balance is above the 60th percentile of the past year, indicating a relatively high level [1]. - In terms of securities lending, there were no shares repaid or sold on August 27, with a lending balance of 0.00 shares, placing it in the 90th percentile of the past year, also indicating a high level [1]. Financial Performance - As of June 30, Anxu Bio had 6,024 shareholders, an increase of 1.50% from the previous period. The average number of circulating shares per shareholder decreased by 1.48% to 21,096 shares [2]. - For the first half of 2025, Anxu Bio reported a revenue of 230 million yuan, a year-on-year decrease of 7.42%. The net profit attributable to shareholders was 59.31 million yuan, down 48.57% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Shareholder Composition - As of June 30, 2025, among the top ten circulating shareholders, Guangfa Value Core Mixed A held 3.01 million shares, unchanged from the previous period. Meanwhile,招商景气优选股票A reduced its holdings by 10,000 shares to 600,000 shares, and博时凤凰领航混合A entered the list as a new shareholder with 528,900 shares [2].

Core Insights - Anxu Biotech's stock increased by 0.86% on August 25, with a trading volume of 38.6154 million yuan [1] - The company reported a financing net purchase of 1.5327 million yuan on the same day, with a total financing balance of 96.5234 million yuan, representing 1.79% of its market capitalization [1] - For the first half of 2025, Anxu Biotech's revenue was 230 million yuan, a year-on-year decrease of 7.42%, and the net profit attributable to shareholders was 59.3059 million yuan, down 48.57% year-on-year [2] Financing and Trading Activity - On August 25, Anxu Biotech had a financing buy amount of 8.0656 million yuan and a financing repayment of 6.5328 million yuan, resulting in a net financing purchase of 1.5327 million yuan [1] - The total financing and securities lending balance was 96.5234 million yuan, which is above the 50th percentile level for the past year, indicating a high level of financing activity [1] - There were no securities lent or sold on August 25, with the securities lending balance also at zero, indicating a lack of short-selling activity [1] Shareholder and Dividend Information - As of June 30, 2025, Anxu Biotech had 6,024 shareholders, an increase of 1.5% from the previous period, while the average number of circulating shares per shareholder decreased by 1.48% to 21,096 shares [2] - The company has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2] - Notable institutional shareholders include GF Value Core Mixed Fund and others, with some changes in holdings reported [2]

Group 1 - The first meeting of the third board of directors of Hangzhou Anxu Biotechnology Co., Ltd. was held on August 22, 2025, with all seven directors present [1] - The board unanimously elected Mr. Ling Shisheng as the chairman of the third board of directors, with a term consistent with the current board [2] - Ms. Jiang Xueying was elected as the vice chairman of the third board of directors, also with a term consistent with the current board [2] Group 2 - The board approved the establishment of specialized committees, including the Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, with terms aligned with the current board [2] - Mr. Ling Shisheng was appointed as the general manager of the company, with a term consistent with the current board [2] - Ms. Jiang Xueying, Mr. Dong Wenkun, and Mr. Wei Wentao were appointed as vice general managers, with terms consistent with the current board [2][3] Group 3 - Ms. Jiang Xueying was appointed as the financial director, with a term consistent with the current board [3] - Mr. Han Jun was appointed as the secretary of the board, with a term consistent with the current board [3] - Ms. Yu Jun was appointed as the representative for securities affairs, with a term consistent with the current board [3]